COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor EP-7041 in ICU Patients
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19
syndrome who based on clinical judgment require care in an intensive care unit, regardless of
whether or not mechanical ventilation is in use or is anticipated. Patients should be
enrolled on the first day of the ICU stay; withdrawal of prior thromboprophylaxis, if any,
will follow specific protocol guidance. Enrolled patients will thereafter be administered
intravenous EP-7041 until disposition from the hospital (including post-ICU non-critical care
management)